Astellas Oncology uses a broad range of scientific thinking for our investigational pipeline. Drug candidates for advanced or resistant disease are our priority.
We utilize the latest science, exploring new technologies, modalities, and biologics.
The safety and efficacy of these agents under investigation have not been established for the use(s) being considered. There is no guarantee that the agent will receive regulatory approval or become commercially available for the use being investigated.
The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China (as of February 2024).
Our clinical research is focused on therapies for hard-to-treat cancers.
Discover clinical trials that might be appropriate for your patients.
You are now leaving www.astellasoncology.com. The website you are linking to is neither owned nor controlled by Astellas. Astellas is not responsible for the content or services on this site.
